Clicky

Cannabis

Mitragynine vs 7-Hydroxymitragynine: Difference, Studies, Side Effects

Mitragynine is kratom's main alkaloid and 7-hydroxymitragynine (7-OH) is a minor one that acts more strongly at the opioid receptor, and this guide explains what the human studies measured and how to read a product label.

Short answer: mitragynine is the main alkaloid in kratom leaf, and 7-hydroxymitragynine (7-OH) is a minor one that binds opioid receptors more strongly. The FDA has not approved kratom as safe and effective for any medical purpose, and FDA’s kratom page says kratom is not lawfully marketed in the U.S. as a drug product, a dietary supplement or a food additive in conventional food. Below is what separates the two, what the human studies actually measured, and what the October 14, 2026 federal notice on 7-OH does and does not do.

Is mitragynine the same as 7-hydroxymitragynine?

No. Both come from the kratom tree (Mitragyna speciosa), but they are present in very different amounts. The DEA’s kratom profile says mitragynine is the most abundant alkaloid, at about 66% of total alkaloid content, while 7-OH is a minor alkaloid at under 2%. FDA says kratom contains over 50 alkaloids, and most research focuses on these two.

The two are chemically related. The October 14, 2026 Federal Register notice describes 7-OH as an active oxidized metabolite of mitragynine in the body, and says it can be made from mitragynine in a one-step chemical reaction. It also says synthetic and naturally occurring 7-OH have identical chemical structures.

Feature Mitragynine 7-hydroxymitragynine (7-OH)
Share of leaf alkaloids About 66% of total alkaloid content (DEA) Under 2% of total alkaloid content in natural leaves (FDA)
Receptor activity Binds mu-opioid receptors, and also acts on serotonin, dopamine, norepinephrine and kappa opioid receptors (FDA) Binds mu-opioid receptors (FDA)
Animal findings In rats, increased breathing rate rather than reducing it (2025 rat breathing study) In rats, 4.5 times morphine’s potency to cut minute volume by 50% (2025 rat breathing study)
Human data A 2025 single-dose study in 15 volunteers, with amounts from 5 to 40 mg Measured in blood alongside mitragynine in a 2026 extract study
Forms it appears in Whole or crushed leaf, powder, extract, encapsulated powder and extract resin “pies” (DEA) Powders, tablets, gummies, sublingual films and liquid shots in concentrated products (Federal Register)
Drug screening Usually enough to produce a positive immunoassay screen, according to Labcorp’s provider FAQ The immunoassay is not designed to detect it directly, according to Labcorp

How much stronger is 7-OH than mitragynine?

FDA says 7-OH “demonstrates substantially greater mu-opioid receptor potency” than mitragynine, and than classical opioids such as morphine. The agency does not give a number for the gap with mitragynine.

The one number in the research compares 7-OH with morphine, and it comes from rats. A 2025 study in the Journal of Pharmacology and Experimental Therapeutics found that 7-OH’s potency to decrease minute volume by 50% was 4.5 times that of morphine. The rats received the drugs intravenously. That is an animal potency ratio, not a comparison of mitragynine and 7-OH in people, and it is not a dose ratio you can apply to any product.

Is kratom comparable to morphine?

In animal studies, in several ways. The DEA’s profile says both mitragynine and 7-OH produce analgesia “similar to morphine,” and that the effect can be blocked by naloxone. In the 2025 rat breathing study, naloxone fully reversed the breathing slowdown caused by both morphine and 7-OH. Mitragynine behaved differently. It increased breathing rate, and naloxone did not change that effect.

In people, the picture is thinner. FDA says there are “few published reports from well-designed scientific studies where kratom was administered to humans.” The Federal Register notice adds that the safety profile of concentrated 7-OH products in humans “remains unknown because no controlled clinical trials have been conducted to establish safe consumption limits or standardized dosing.”

Will mitragynine get me high?

The human studies measured how people feel, and the answer depends on the amount and the product. In a 2025 phase 1 study of 15 healthy volunteers, the 5 mg amount raised ratings of arousal and attention. The 40 mg amount increased ratings of amnesia and produced mild psychopathological symptoms.

A 2026 pilot study in the Journal of Clinical Psychopharmacology enrolled 40 recreational polydrug users who had experience with opioids, in cohorts of eight. Six in each cohort received a single dose of kratom leaf and two received placebo, with doses of 1, 3, 8, 10 and 12 grams. Its highest dose, 12 grams, increased several subjective measures, including ratings of “drug liking” and “high.” The study’s authors noted the kratom was single-sourced and may not represent other products.

A 2026 study in Drug Testing and Analysis randomized 116 healthy, kratom-naive adults: 49 received Mitra-Leaf kratom leaf powder capsules and 67 received placebo. Participants took a single oral dose or 15 consecutive daily doses. The study found subjective effects that were “modest, dose-related,” and responses that decreased after repeated dosing.

FDA’s kratom page, current as of its December 2025 update, says a well-designed human abuse potential study has not yet been conducted, and that FDA awarded a grant for one in September 2024. The Federal Register also cites anecdotal user reports describing 7-OH as “the cleanest and most euphoric high.” That is user talk, not a study. For a wider look at kratom studies, see kratom benefits evidence (our research library).

Is 50 mg of mitragynine a lot?

The research does not give a safe amount, and this guide will not name one. What the studies tested were research amounts in controlled settings. The 2025 phase 1 study gave single amounts of 5, 10, 20 and 40 mg of isolated mitragynine. In the 2026 MitraLeaf trial, the single-dose groups received 6.65 to 53.2 mg of mitragynine in leaf powder. So 50 mg sits near the top of the amounts these studies tested.

A label will not settle it either. The Federal Register notice says 7-OH products ranged from 1 mg to 700 mg in a single dose or serving in the market data it cites, and it raises concern about standardized dosing. If you are weighing a specific amount, a clinician is the person to ask, especially if you take other medicines.

What does green kratom do, and is green or white kratom more energizing?

Color names like green or white describe the product, not a measured alkaloid level. The DEA’s profile says alkaloid content “varies significantly based on factors like plant strain and maturity,” so a color name cannot tell you how much mitragynine or 7-OH is in a product. For the same reason, color cannot tell you which one will feel more energizing.

What is documented is how people describe kratom’s effects. NCCIH says people report stimulant-like effects, including “increased energy, alertness, rapid heart rate,” and opioid-like effects, including “relaxation, pain relief, confusion.” The DEA notes that at low doses, kratom produces stimulant effects, with users reporting increased alertness, physical energy, talkativeness and sociable behavior.

What are the side effects of mitragynine and 7-OH?

Effect What the source reports
Mild effects Nausea, constipation, dizziness and drowsiness (NCCIH)
Acute effects Nausea, itching, sweating, dry mouth, constipation, increased urination and loss of appetite (DEA)
Rare but serious effects Seizures, high blood pressure and liver problems (NCCIH). FDA also lists liver toxicity and seizures among the serious adverse events it warns about.
Breathing FDA says classic opioid-related effects can include respiratory depression that may lead to death. In the 2025 rat study, 7-OH caused breathing depression that naloxone fully reversed.
Dependence and withdrawal Regular users may have withdrawal symptoms when they stop (NCCIH). FDA reports cases of substance use disorder with tolerance and withdrawal.
Newborns FDA is aware of neonatal abstinence syndrome, with withdrawal signs such as jitteriness, irritability and muscle stiffness after prolonged exposure before birth.
Reported in the 2026 MitraLeaf trial After single doses: dizziness, nausea and feeling of relaxation. After 15 daily doses: headache, feeling hot, increased alanine aminotransferase level and nausea. The trial reported no serious adverse events or deaths.

Two statements from the agencies help put deaths in context. FDA says deaths have been associated with kratom, but kratom “was usually used in combination with other drugs, and the contribution of kratom in the deaths is unclear.” NCCIH says fatal overdoses from kratom alone “appear to be extremely rare.” Reports are not rates. A CDC analysis of kratom exposure reports from 53 U.S. poison centers, covering 2015 to 2025, counts contacts that prompted a poison center call, whatever the toxicity. The DEA’s profile says FDA’s Adverse Event Reporting System shows kratom “co-involved” in 1,720 cases from 2008 to 2026, with 765 involving death. These are reports of kratom involvement, and they do not show cause.

If you have a bad reaction to a product containing 7-OH, FDA asks you to report it through MedWatch. You can call 1-800-332-1088 to request a form.

Who should talk to a clinician first?

Talk with a clinician before using kratom if any of these fit you:

  • Pregnancy or breastfeeding. FDA’s newborn findings above are the reason for this one.
  • Prescription medicines. In a clinical interaction study of 12 healthy adults, a single 2 g kratom tea modestly increased midazolam exposure, a drug used as a CYP3A test. The study says co-consuming kratom with certain CYP3A-metabolized drugs “may precipitate serious interactions.”
  • Liver disease. FDA lists liver toxicity among the risks it warns about, and NCCIH lists liver problems among the rare serious effects.
  • A history of substance use. FDA reports cases of kratom-related substance use disorder, and NCCIH says kratom itself may have the potential to be addictive.

Will 7-OH or mitragynine show up on a drug test?

Labcorp, a clinical laboratory, answers these questions in its provider FAQ.

Will 7-hydroxymitragynine fail a drug test?

Labcorp says its immunoassay is not designed to detect 7-OH directly. But 7-OH products commonly contain mitragynine, and Labcorp says mitragynine is typically enough to produce a positive screen in most cases. It also says it is not commonly seeing 7-OH detected without mitragynine. So a 7-OH product often shows up through its mitragynine.

Is there a false positive?

Labcorp says there are some situations where false positives can occur with the immunoassay. It describes presumptive immunoassay testing as the usual first step in most clinical settings, with mass spectrometry available as definitive testing when appropriate.

Is there a 7-OH urine test?

One urine figure in this research comes from a 2025 study of 51 postmortem cases in the Journal of Analytical Toxicology. In those cases, the average mitragynine to 7-OH ratio in urine was 16.9. Those were deceased people, so the number describes postmortem samples, not a test on a living person. The same study found that 7-OH was stable refrigerated for up to 7 days, with less than 20% loss, while mitragynine was stable for up to 30 days.

If a test is coming up, ask the testing lab or the person ordering it which test they run, and whether it is a screen or a confirmation. For a different compound, the delta 9 drug test guide covers how that substance shows on screens, and thc still shows in urine covers the urine side of THC.

What is the October 14, 2026 Federal Register notice on 7-OH?

What a notice of intent is

A notice of intent is DEA’s public announcement that it plans to issue a temporary scheduling order. It is not the order itself. The October 14 document is labeled “Proposed amendment; notice of intent.” The notice says that when a temporary order is issued, it “will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances.” A separate document in the same issue withdraws DEA’s July 2026 notice of intent for 7-OH.

What it proposes

The notice follows an HHS letter dated October 8, 2026. HHS recommended that 7-OH and mitragynine pseudoindoxyl (MGPI) be controlled in Schedule I when either one alone, or their combined amount, is above 1 milligram per gram in solid products or 1 milligram per milliliter in liquids. It also recommended that the threshold apply when the ratio of mitragynine to 7-OH, MGPI or their combined amount is less than 100 to 1. The notice says this threshold “would permit certain products to remain in the marketplace without being subject to schedule I controls,” and it adds that neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels. FDA’s 7-OH products page summarizes the same recommendation.

What is already in place

Kratom itself is not controlled under the Controlled Substances Act. The DEA’s profile calls it “an unscheduled botanical.” DEA temporarily placed mitragynine pseudoindoxyl, MGM-15 and MGM-16 into Schedule I on August 26, 2026, and those controls remain in effect until DEA issues a new temporary scheduling order. The October notice is a proposal, not a final order.

State and local rules differ. FDA says state health and law enforcement agencies are the best resource on state laws.

How do I tell from a label which one a product is built on?

A label can give you clues about the product. It cannot give you the alkaloid amounts by itself.

What the label shows What it suggests
Kratom leaf or leaf powder as the only ingredient A botanical leaf product. FDA says 7-OH is under 2% of the alkaloids in natural leaves.
7-hydroxymitragynine or MGPI listed as an ingredient More than leaf. The Federal Register says concentrated 7-OH products contain a significantly higher concentration of 7-OH than botanical kratom.
Tablets, gummies, sublingual films, liquid shots or chewable tablets Forms the Federal Register associates with concentrated 7-OH products.
Terms such as “natural M. speciosa extract,” “precision-formulated,” “botanical extract” or “mood booster” Marketing terms the DEA says sellers use. The DEA says this branding “creates a false sense of safety.”
An extract ratio or a strain color Neither tells you the alkaloid mix, because the DEA says alkaloid content varies with strain and maturity.

What’s the strongest kratom?

This guide does not rank kratom by strength, potency or effect, and no label reliably settles it. The Federal Register notes that 7-OH product concentrations varied from 1 mg to 700 mg in a single dose or serving, which is a reason to check the lab report for the specific product rather than trust a strength claim.

Before you order: what to check

  • A lab report matched to the lot number, showing the mitragynine and 7-OH amounts.
  • The full ingredient list, checked for 7-OH and MGPI.
  • The warnings and any age limit on the label or product page.
  • The written return terms: what is covered, how long you have, and what you must send back.

Read the Federal Register notice and the FDA’s kratom page for current federal status, and check your state and local rules before you decide.

By HealthDataConsortium.org Research Team

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.